Abstract
One of the first signs of ischemic heart disease may manifest as chronic stable angina, a mismatch between oxygen supply and demand. With more than approximately 16.5 million people each year having stable angina, development of new therapies to help control this disease state are warranted. Ranolazine, a novel agent exerting its effect through a partial fatty oxidase inhibitor, is one of the first new drugs in more than 20 years to be developed for chronic stable angina. Working through enzymatic modulation, instead of altering myocardial hemodynamics, ranolazine appears to be effective. An overview of chronic stable angina is provided, the American College of Cardiology-American Heart Association (ACC-AHA) current pharmacologic treatment guidelines are reviewed, and the mechanism of action of ranolazine is explored. Finally, the major clinical trials supporting its place in medical therapy are discussed. Additional clinical trials are under way to further elucidate ranolazine's exact role in the treatment of chronic stable angina. From results of the existing phase III clinical trials, however, the most beneficial potential role of ranolazine in the treatment algorithm of chronic stable angina appears to be as adjunctive ther...Continue Reading
References
Aug 1, 1994·Circulation·U ThadaniY K Chiang
Jan 1, 1996·Circulation·J G McCormackG D Lopaschuk
Jan 21, 1997·Circulation·G D Lopaschuk, W C Stanley
Apr 29, 1998·General Pharmacology·J G McCormackA A Wolff
Jul 15, 1999·The American Journal of Cardiology·C J Pepine, A A Wolff
May 4, 2002·Heart Failure Reviews·Nandakumar SambandamMichael F Allard
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Peter Berger
Apr 16, 2004·European Heart Journal·Leong LeeMichael Frenneaux
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Justin S Hooper, Anthony J Busti
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Christoph Pechlaner, Christian Wiedermann
Oct 12, 2004·Mayo Clinic Proceedings·Eric H YangAmir Lerman
Jan 27, 2005·The American Journal of Cardiology·Michel F RousseauAndrew A Wolff
Mar 22, 2005·Journal of Clinical Pharmacology·Markus JerlingZiad Hussein
Jun 14, 2005·Journal of Clinical Pharmacology·Hisham Abdallah, Markus Jerling
Citations
Jul 6, 2006·Nature Reviews. Drug Discovery·Jonathan AbramsPeter Kirkpatrick
Jun 28, 2011·Nature Reviews. Drug Discovery·David C Swinney, Jason Anthony
Jan 22, 2011·Journal of Cardiovascular Medicine·Catherine NortonJaved Butler
Sep 1, 2006·Photomedicine and Laser Surgery
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Thorsten Reffelmann, Robert A Kloner
Aug 25, 2012·Expert Opinion on Investigational Drugs·Stylianos Tzeis, George Andrikopoulos
Dec 15, 2015·Scientific Reports·Anne VirsolvySylvain Richard
Feb 14, 2007·Clinical Therapeutics·Judy W M Cheng
Nov 17, 2009·JACC. Cardiovascular Imaging·Rajesh VenkataramanAmi E Iskandrian
Nov 14, 2016·International Journal of Cardiology·Kinjal BanerjeeAnjan Gupta
Aug 29, 2013·Journal of Biomolecular Screening·David C Swinney